Jupiter Neurosciences Raises $3.6M via 11.47M Share Sale Under SEPA, Pushing Outstanding Shares to 56.5M

summarizeSummary

Jupiter Neurosciences sold 11.47 million shares for ~$3.6M under its SEPA with Yorkville, increasing outstanding shares to 56.5 million. The deeply discounted sales continue a pattern of dilutive financing amid severe financial distress.

check_boxKey Events · Financing and Capital Events · JUNS

• 11.47M Shares Sold for $3.6M

  Between May 14 and July 24, 2026, Jupiter sold 11.47 million shares to Yorkville under the SEPA, raising approximately $3.6 million in gross proceeds.

• Deeply Discounted Pricing

  Shares were sold at 97% of the lowest daily VWAP during each three-day pricing period, a structure that typically results in significant discounts to market price.

• Outstanding Shares Surge to 56.5M

  Following the sales, outstanding shares reached 56,520,143 as of July 28, 2026, representing roughly 20% dilution from the new issuance alone.

• Ongoing Distressed Financing

  This is the latest in a series of dilutive financings; the company has a going concern warning, Nasdaq delisting threat, and continues to burn cash.

auto_awesomeAnalysis · JUNS · Life Sciences

Between May 14 and July 24, 2026, Jupiter Neurosciences sold 11.47 million shares to Yorkville under its SEPA, generating approximately $3.6 million in gross proceeds. The pricing mechanism—a 3% discount to the lowest VWAP during each pricing period—creates a deeply dilutive structure. With the stock trading at $0.1075, these newly issued shares account for roughly 20% of the now 56.5 million outstanding shares, significantly eroding existing holders' stakes. This transaction extends a pattern of distressed financing as the company contends with cash burn, a going concern warning, and a Nasdaq delisting threat. While the capital provides short-term runway, it comes at a steep cost to shareholders.